Gandotinib

Drug Profile

Gandotinib

Alternative Names: LY2784544

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class 2 ring heterocyclic compounds; Antineoplastics; Small molecules
  • Mechanism of Action Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myeloproliferative disorders
  • Phase I Myelofibrosis
  • Preclinical Solid tumours

Most Recent Events

  • 08 Sep 2015 Gandotinib is still in phase II trials for Myeloproliferative disorders in the USA, Austria, Australia, Canada, France, Germany, Italy, Spain and Sweden
  • 13 Jul 2012 Phase-II clinical trials in Myeloproliferative disorders in Spain (PO)
  • 30 Jun 2012 Eli Lilly completes a phase I trial in Healthy volunteers in USA (NCT01577355)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top